Celularity (NASDAQ:CELU) Stock Price Down 0.6% – What’s Next?

Celularity, Inc. (NASDAQ:CELU)’s stock price dropped 0.6% on Monday . The stock traded as low as $1.73 and last traded at $1.77. Approximately 65,450 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 146,880 shares. The stock had previously closed at $1.78.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CELU. Weiss Ratings reissued a “sell (d-)” rating on shares of Celularity in a research report on Wednesday, October 8th. Wall Street Zen lowered Celularity from a “hold” rating to a “sell” rating in a report on Friday, September 5th. Finally, WBB Securities upgraded shares of Celularity from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a research report on Tuesday, September 9th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Celularity Stock Performance

The company has a market cap of $47.24 million, a price-to-earnings ratio of -0.56 and a beta of 0.76. The company has a fifty day moving average of $2.09 and a two-hundred day moving average of $2.35.

Celularity (NASDAQ:CELU) last issued its quarterly earnings data on Friday, August 29th. The company reported ($1.02) earnings per share (EPS) for the quarter. Celularity had a negative net margin of 165.22% and a negative return on equity of 459.57%. The business had revenue of $5.74 million during the quarter.

Institutional Trading of Celularity

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in Celularity by 35.3% during the 3rd quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock worth $1,401,000 after purchasing an additional 176,518 shares during the last quarter. Valmark Advisers Inc. acquired a new stake in shares of Celularity in the second quarter valued at about $98,000. HB Wealth Management LLC bought a new position in shares of Celularity during the third quarter worth about $84,000. Bank of America Corp DE lifted its stake in shares of Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after acquiring an additional 35,023 shares during the period. Finally, XTX Topco Ltd boosted its holdings in Celularity by 106.4% in the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after acquiring an additional 11,057 shares during the last quarter. Institutional investors own 19.02% of the company’s stock.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.